의료용 대마사용에 대한 법제 비교 연구

초록

Cannabis is commonly known as a drug, but it also has medical applications, and its use is legally sanctioned in 68 countries. The development of hemp-based drugs has been particularly active globally since the creation of epilepsy treatments using hemp in 2018. These efforts have expanded patient treatment options and aimed to capture the high value-added market. In Korea, however, despite the revision of the 「Act on the Management of Narcotics」 in 2018 to permit medical hemp use, only authorized imports from overseas are allowed. This has stifled domestic development, preventing Korea from keeping pace with global trends. Meanwhile, social concerns and negative perceptions about hemp persist, exacerbated by high-profile cases of celebrities using cannabis. This study examined global regulatory trends in hemp and proposed ways to improve Korea's 「Act on the Management of Narcotics」 to facilitate the medical use of non-psychoactive hemp. The research included an analysis of policy changes in the United States, Canada, Germany, France, and Japan regarding the legalization of medical cannabis and the promotion of the hemp industry. Notably, Japan, with a legal system similar to Korea's, revised its 「Cannabis Control Act」 to the 「Act on the Regulation of Cannabis Cultivation」, distinguishing between cannabis cultivators and hemp research growers. This study suggests regulatory improvements based on these international examples to achieve full legalization of medical cannabis use in Korea.

키워드